Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Applied Health Economics and Health Policy
Erschienen in: Applied Health Economics and Health Policy 2/2012

01.03.2012 | Original Research Article

A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries

verfasst von: Dr Sergio Iannazzo, Michela Carsi, Silvia Chiroli

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

A probabilistic patient-level Markov model was previously developed to simulate lifetime clinical and economic outcomes of cinacalcet treatment in secondary hyperparathyroidism (SHPT) patients using local data from Italy. The present study extends the application of the model to four other European countries — Spain, Portugal, Switzerland and the Czech Republic — in order to assess the consistency of results.

Methods

Cinacalcet influences the levels of parathyroid hormone, serum calcium and phosphorous. Our simulation was based on data from the OPTIMA (Open-Label, Randomized Study Using Cinacalcet to Improve Achievement of KDOQI Targets in Patients with End-Stage Renal Disease) randomized controlled trial and from published correlations between bone-metabolism parameters, mortality and morbidity (cardiovascular [CV] events, fractures and parathyroidectomy). Local epidemiological and cost data for dialysis, drugs and event management were incorporated into the model. The simulation horizon was patient lifetime; standard treatment for SHPT (vitamin D sterols and phosphate binders) and cinacalcet plus standard treatment were compared. Effectiveness was measured in terms of life expectancy (LE) and quality-adjusted life expectancy (QALE). Health utility indexes derived from published literature took into account dialysis, CV events and fractures.

Results

The simulated mean LE extension in patients receiving cinacalcet was 1.20 life-years (LY) in Italy, 1.10 LY in Spain, 1.18 LY in Portugal, 1.10 LY in the Czech Republic and 1.40 LY in Switzerland. QALE increase was 0.89, 0.82, 0.89, 0.80 and 1.01 QALY in the same countries, respectively. The incremental cost-effectiveness ratio (ICER) result was €23 500/LY and €31600/QALY in Italy, €21800/LY and €29 300/QALY in Spain, €23 700/LY and €31 200/QALY in Portugal, €29 700/LY and €40 800/QALY in the Czech Republic and €24 700/LY and €34 200/QALY in Switzerland. Including dialysis costs as a part of the total costing doubled the ICER, from a minimum of €42 800/LY in Spain to a maximum of €82 800/LY in Switzerland and in the range from €57 500/QALY (Spain) to €114 700/QALY (Switzerland).

Conclusion

Taking into consideration the limited clinical, epidemiological and health economics data available, cinacalcet treatment showed a relatively good cost-effectiveness profile in all the countries analysed, despite the differences in their healthcare systems and economic wealth.
Literatur
1.
Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24(5): 1506–23PubMedCrossRef
2.
Goldsmith D, Kothawala P, Chalian A, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of fracture and need for parathyroidectomy in CKD. Am J Kidney Dis 2009; 53(6): 1002–13PubMedCrossRef
3.
Eknoyan G, Levin A, Levin N. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42Suppl. 3: S1–201CrossRef
4.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; (113): S1–130
5.
Messa P, Macario F, Yaqoob M, et al. The OPTIMA Study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36–45PubMedCrossRef
6.
Eandi M, Pradelli L, Iannazzo S, et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010; 28: 1041–54PubMedCrossRef
7.
Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005; 20: 2186–93PubMedCrossRef
8.
Cunningham J, Urena P, Reichel H, et al. Long-term (5-year) efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end stage renal disease (CKD STAGE 5) [abstract]. XLII Congress of the ERA-EDTA; 2005 June 4-7; Istanbul, Turkey
9.
Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality and morbidity in maintenance haemodialysis. J Am Soc Nephrol 2004; 15: 2208–18PubMedCrossRef
10.
Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3 and 4 study. J Am Soc Nephrol 2005; 16: 1788–93PubMedCrossRef
11.
Trespalacios FC, Taylor AJ, Agodoa LY, et al. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003; 41(6): 1267–77PubMedCrossRef
12.
Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358–66PubMedCrossRef
13.
Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of parathyroidectomy in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Hemodial Int 2007; 11(1): 62–71PubMedCrossRef
14.
Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66: 2010–6PubMedCrossRef
15.
Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007; 11(18): iii, xi-xiii, 1-167
16.
de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998; 44: 215–32PubMedCrossRef
17.
Nichol G, Kaul P, Huszti E, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004; 141: 343–51PubMed
18.
Martin AJ, Glasziou PP, Simes RJ. A cardiovascular extension of the Health Measurement Questionnaire. J Epidemiol Community Health 1999; 53: 548–57PubMedCrossRef
19.
Nease RFJ, Kneeland T, O’Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina: implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA 1995; 273: 1185–90PubMedCrossRef
20.
Brazier JE, Green C, Kanis JA, Committee of Scientific Advisors International Osteoporosis Foundation. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporosis Int 2002; 13: 768–76CrossRef
21.
Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care. New York: Oxford University Press, 2001: 172–214
22.
23.
24.
25.
26.
27.
S.E.N: Sociedad Española de Nefrología. Report of 2007. XXXVIII Congress of the Sociedad Española de Nefrología; 2008 Oct 4-7; San Sebastían
28.
29.
30.
de Jager DJ, Grootendorst DC, Jager K J, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302: 1782–9PubMedCrossRef
31.
L’Informatore Farmaceutico. Italian directory of medicines and manufacturers. 69th Rev. Milan: Elsevier, 2009
32.
Spanish Official Drug List. Catálogo de Especialidades Farmacéuticas. Consejo General de Colegios. Madrid: Oficiales de Farmacéuticos, 2007
33.
34.
35.
36.
Nomenclatore Tariffario Nazionale: DRG tariffs. DMS 2006 Sep 12. Supplemento Ordinario alla Gazzetta Ufficiale 2006 Dec 13; 289
37.
38.
39.
40.
41.
42.
43.
44.
45.
Bulková V, Fiala M, Chovančík J, et al. Analýza nákladů na léčbu u pacientů s fibrilací sini v České republice. Cor Vasa 2008; 50(1): 23–7
46.
Ondráčková B, Barbora-Miklík R, Roman-Pařenica J, et al. Náklady a délka hospitalizace u pacientů s akutním srdečním selháním. Farmakoekonomika 2007; 2(2): 50–5
47.
Ondráčková B, Barbora-Miklík R, Roman-Pařenica J, et al. Costs and length of stay in patients hospitalized for acute heart failure [abstract]. Value Health 2007; 10(6): A418CrossRef
48.
Marie H, Pavel K, Libor S, et al. Management and cost of stroke in late nineties: Prague university hospital. Acta Clin Croat 2001; 40: 79–84
49.
Cunningham J, Danese MD, Olson KA, et al. Effects of the calcimimetic cinacalcet HCI on cardiovascular disease, fracture, and health related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793–800PubMedCrossRef
50.
Eandi M, Giotta N, Santagostino Barbone G. Analisi costo/efficacia di sevelamer nel trattamento dell’iperfosforemia del paziente in dialisi. Farmeconomia e Percorsi Terapeutici 2004; 5: 201–18
51.
52.
Sandoz MS, Ess SM, Keusch GW, et al. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001. Swiss Med Wkly. 2004; 134: 448–58PubMed
53.
Opatrný Jr K, Třeška V. Koncepce oboru nefrologie v Ceské republice. Aktuality v nefrologii 2001; 7: 118–26
54.
Metadaten
Titel
A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries
verfasst von
Dr Sergio Iannazzo
Michela Carsi
Silvia Chiroli
Publikationsdatum
01.03.2012
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 2/2012
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.2165/11597980-000000000-00000

Weitere Artikel der Ausgabe 2/2012

Applied Health Economics and Health Policy 2/2012 Zur Ausgabe

Original Research Article

Evaluating the epidemiology and morbidity burden associated with human papillomavirus in Israel

Current Opinion

Using the economics of certification to improve the safety and quality of male circumcision in developing countries

Original Research Article

Insights from triangulation of two purchase choice elicitation methods to predict social decision making in healthcare

Research Letter

Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain

Original Research Article

Understanding consumer preferences in the context of managed competition

Correspondence

The need for measurement of efficiency in Greek primary healthcare